• Acorda Therapeutics Inc., of Hawthorne, N.Y., reported third quarter 2011 revenues of $93 million, edging ahead of analyst estimates of $91 million. Revenues from Ampyra (dalfampridine) for multiple sclerosis mobility were $54.7 million, also just ahead of expectations. Acorda's GAAP net income for the third quarter was $18.9 million, or 47 cents per share. The firm had $268.8 million in cash, equivalents and investments as of Sept. 30. Analysts were pleased to see Ampyra keeping pace with expectations, and shares (NASDAQ:ACOR) gained $2.63, or 13 percent, to close at $23.08 on Friday.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST